These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19253387)

  • 1. Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross-sectional cohort study.
    Christiaans I; van Langen IM; Birnie E; Bonsel GJ; Wilde AA; Smets EM
    Am J Med Genet A; 2009 Feb; 149A(4):602-12. PubMed ID: 19253387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy.
    Christiaans I; Birnie E; Bonsel GJ; Mannens MM; Michels M; Majoor-Krakauer D; Dooijes D; van Tintelen JP; van den Berg MP; Volders PG; Arens YH; van den Wijngaard A; Atsma DE; Helderman-van den Enden AT; Houweling AC; de Boer K; van der Smagt JJ; Hauer RN; Marcelis CL; Timmermans J; van Langen IM; Wilde AA
    Eur Heart J; 2011 May; 32(9):1161-70. PubMed ID: 21459882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic counseling and cardiac care in predictively tested hypertrophic cardiomyopathy mutation carriers: the patients' perspective.
    Christiaans I; van Langen IM; Birnie E; Bonsel GJ; Wilde AA; Smets EM
    Am J Med Genet A; 2009 Jul; 149A(7):1444-51. PubMed ID: 19533783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening.
    Christiaans I; Birnie E; van Langen IM; van Spaendonck-Zwarts KY; van Tintelen JP; van den Berg MP; Atsma DE; Helderman-van den Enden AT; Pinto YM; Hermans-van Ast JF; Bonsel GJ; Wilde AA
    Eur Heart J; 2010 Apr; 31(7):842-8. PubMed ID: 20019025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical predictors of a positive genetic test in hypertrophic cardiomyopathy in the Brazilian population.
    Marsiglia JD; Credidio FL; de Oliveira TG; Reis RF; Antunes Mde O; de Araujo AQ; Pedrosa RP; Barbosa-Ferreira JM; Mady C; Krieger JE; Arteaga-Fernandez E; Pereira AC
    BMC Cardiovasc Disord; 2014 Mar; 14():36. PubMed ID: 24625281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphological and functional abnormalities pattern in hypertrophy-free HCM mutation carriers detected with echocardiography.
    Peyrou J; Réant P; Reynaud A; Cornolle C; Dijos M; Rooryck-Thambo C; Landelle M; Montaudon M; Laurent F; Roudaut R; Lafitte S
    Int J Cardiovasc Imaging; 2016 Sep; 32(9):1379-1389. PubMed ID: 27324645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychological distress in the 5-year period after predictive testing for Huntington's disease.
    Decruyenaere M; Evers-Kiebooms G; Cloostermans T; Boogaerts A; Demyttenaere K; Dom R; Fryns JP
    Eur J Hum Genet; 2003 Jan; 11(1):30-8. PubMed ID: 12529703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel deletions in MYH7 and MYBPC3 identified in Indian families with familial hypertrophic cardiomyopathy.
    Waldmüller S; Sakthivel S; Saadi AV; Selignow C; Rakesh PG; Golubenko M; Joseph PK; Padmakumar R; Richard P; Schwartz K; Tharakan JM; Rajamanickam C; Vosberg HP
    J Mol Cell Cardiol; 2003 Jun; 35(6):623-36. PubMed ID: 12788380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obtaining insurance after DNA diagnostics: a survey among hypertrophic cardiomyopathy mutation carriers.
    Christiaans I; Kok TM; van Langen IM; Birnie E; Bonsel GJ; Wilde AA; Smets EM
    Eur J Hum Genet; 2010 Feb; 18(2):251-3. PubMed ID: 19672285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mental health and quality of life after genetic testing for Huntington disease: a long-term effect study in Germany.
    Licklederer C; Wolff G; Barth J
    Am J Med Genet A; 2008 Aug; 146A(16):2078-85. PubMed ID: 18627060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
    Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
    Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of sense of coherence with psychological distress and quality of life in inflammatory bowel disease.
    Freitas TH; Andreoulakis E; Alves GS; Miranda HL; Braga LL; Hyphantis T; Carvalho AF
    World J Gastroenterol; 2015 Jun; 21(21):6713-27. PubMed ID: 26074710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Contemporary Family Screening in Hypertrophic Cardiomyopathy.
    van Velzen HG; Schinkel AFL; Baart SJ; Oldenburg RA; Frohn-Mulder IME; van Slegtenhorst MA; Michels M
    Circ Genom Precis Med; 2018 Apr; 11(4):e001896. PubMed ID: 29661763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life and psychological distress in patients with Peutz-Jeghers syndrome.
    van Lier MG; Mathus-Vliegen EM; van Leerdam ME; Kuipers EJ; Looman CW; Wagner A; Vanheusden K
    Clin Genet; 2010 Sep; 78(3):219-26. PubMed ID: 20695872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and genetic diagnosis of familial hypertrophic cardiomyopathy: Results in pediatric cardiology.
    Cardoso B; Gomes I; Loureiro P; Trigo C; Ferreira Pinto F
    Rev Port Cardiol; 2017 Mar; 36(3):155-165. PubMed ID: 28214152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers.
    Michels M; Soliman OI; Phefferkorn J; Hoedemaekers YM; Kofflard MJ; Dooijes D; Majoor-Krakauer D; Ten Cate FJ
    Eur Heart J; 2009 Nov; 30(21):2593-8. PubMed ID: 19666645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole exome sequencing combined with integrated variant annotation prediction identifies a causative myosin essential light chain variant in hypertrophic cardiomyopathy.
    Nomura A; Tada H; Teramoto R; Konno T; Hodatsu A; Won HH; Kathiresan S; Ino H; Fujino N; Yamagishi M; Hayashi K
    J Cardiol; 2016 Feb; 67(2):133-9. PubMed ID: 26443374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYH7 Gene-Related Mutation p.V878L Identified in a Chinese Family with Hypertrophic Cardiomyopathy.
    Du Y; Wang Y; Han X; Feng Z; Ma A
    Int Heart J; 2019 Nov; 60(6):1415-1420. PubMed ID: 31735781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing.
    Jensen MK; Havndrup O; Christiansen M; Andersen PS; Diness B; Axelsson A; Skovby F; Køber L; Bundgaard H
    Circulation; 2013 Jan; 127(1):48-54. PubMed ID: 23197161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy.
    Ingles J; McGaughran J; Scuffham PA; Atherton J; Semsarian C
    Heart; 2012 Apr; 98(8):625-30. PubMed ID: 22128210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.